RU2001116080A - THERAPEUTIC AGENT FOR SUPPRESSING NOISE OF TAP - Google Patents

THERAPEUTIC AGENT FOR SUPPRESSING NOISE OF TAP

Info

Publication number
RU2001116080A
RU2001116080A RU2001116080/14A RU2001116080A RU2001116080A RU 2001116080 A RU2001116080 A RU 2001116080A RU 2001116080/14 A RU2001116080/14 A RU 2001116080/14A RU 2001116080 A RU2001116080 A RU 2001116080A RU 2001116080 A RU2001116080 A RU 2001116080A
Authority
RU
Russia
Prior art keywords
bont
use according
clostridial toxin
paragraphs
complex
Prior art date
Application number
RU2001116080/14A
Other languages
Russian (ru)
Other versions
RU2243783C2 (en
Inventor
Ханс БИГАЛЬКЕ
Йюрген ФРЕФЕРТ
Original Assignee
Биотекон Гезелльшафт Фюр Биотекнологише Энтвиклунг Унд Консультинг Мбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19856897A external-priority patent/DE19856897A1/en
Application filed by Биотекон Гезелльшафт Фюр Биотекнологише Энтвиклунг Унд Консультинг Мбх filed Critical Биотекон Гезелльшафт Фюр Биотекнологише Энтвиклунг Унд Консультинг Мбх
Publication of RU2001116080A publication Critical patent/RU2001116080A/en
Application granted granted Critical
Publication of RU2243783C2 publication Critical patent/RU2243783C2/en

Links

Claims (11)

1. Применение высокоочищенного токсина клостридий BoNT/A для производства терапевтического агента, предназначенного для внутримышечного введения, для подавления шумов храпа.1. The use of highly purified BoNT / A clostridial toxin for the manufacture of a therapeutic agent intended for intramuscular administration to suppress snoring noise. 2. Применение высокоочищенного токсина клостридий BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F и/или BoNT/G для производства терапевтического агента, предназначенного для внутримышечного введения, для подавления шумов храпа. 2. The use of highly purified clostridial toxin BoNT / B, BoNT / C1, BoNT / D, BoNT / E, BoNT / F and / or BoNT / G for the manufacture of a therapeutic agent intended for intramuscular administration to suppress snoring noise. 3. Применение высокоочищенного токсина клостридий ТеNТ для производства терапевтического агента, предназначенного для внутримышечного введения, для подавления шумов храпа. 3. The use of high purity toxin of Clostridium TeNT for the production of a therapeutic agent intended for intramuscular administration to suppress snoring noise. 4. Применение комплекса, включающего в себя токсин клостридий или гибридный белок и один или более чем один терапевтически хорошо переносимый гемагглютинин и/или один или более чем один фармацевтически хорошо переносимый нетоксичный белок, для производства лекарства, предназначенного для введения внутримышечным путем, для подавления шумов храпа. 4. The use of a complex comprising a clostridial toxin or fusion protein and one or more therapeutically well tolerated hemagglutinin and / or one or more pharmaceutically well tolerated non-toxic proteins for the manufacture of a medicament for administration by intramuscular route to suppress noise snoring. 5. Применение по любому из пп. 1-4, отличающееся тем, что дополнительно применяют комплекс одного или более чем одного терапевтически хорошо переносимого гемагглютинина и/или одного или более чем одного фармацевтически хорошо переносимого нетоксичного белка. 5. The use according to any one of paragraphs. 1-4, characterized in that it further uses a complex of one or more therapeutically well tolerated hemagglutinin and / or one or more than one pharmaceutically well tolerated non-toxic protein. 6. Применение по п. 5, отличающееся тем, что применяют комплекс дикого типа. 6. The use according to claim 5, characterized in that the wild-type complex is used. 7. Применение по любому из пп. 1-6, отличающееся тем, что токсин клостридий представляет собой рекомбинантный белок. 7. The use according to any one of paragraphs. 1-6, characterized in that the clostridial toxin is a recombinant protein. 8. Применение по любому из пп. 1-7, отличающееся тем, что токсин клостридий представляет собой лиофилизированный продукт. 8. The use according to any one of paragraphs. 1-7, characterized in that the clostridial toxin is a lyophilized product. 9. Применение по любому из пп. 1-7, отличающееся тем, что он представлен в виде водного раствора, в частности, в виде водного инъекционного раствора. 9. The use according to any one of paragraphs. 1-7, characterized in that it is presented in the form of an aqueous solution, in particular, in the form of an aqueous injection solution. 10. Применение по п. 9, отличающееся тем, что токсин клостридий или его комплекс представлен в виде раствора в физиологическом растворе. 10. The use according to claim 9, characterized in that the clostridial toxin or its complex is presented as a solution in physiological saline. 11. Применение по любому из пп. 1-7, отличающееся липосомами в качестве носителей для токсина клостридий или его комплекса. 11. The use according to any one of paragraphs. 1-7, characterized by liposomes as carriers for the toxin of clostridia or its complex.
RU2001116080/14A 1998-12-10 1999-12-10 Therapeutic agent for suppression of snore noise RU2243783C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19856897A DE19856897A1 (en) 1998-12-10 1998-12-10 Therapeutic to suppress snoring noises
DE19856897.5 1998-12-10

Publications (2)

Publication Number Publication Date
RU2001116080A true RU2001116080A (en) 2003-03-20
RU2243783C2 RU2243783C2 (en) 2005-01-10

Family

ID=7890562

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001116080/14A RU2243783C2 (en) 1998-12-10 1999-12-10 Therapeutic agent for suppression of snore noise

Country Status (21)

Country Link
US (1) US6573241B1 (en)
EP (1) EP1137430B1 (en)
JP (1) JP4700811B2 (en)
KR (1) KR100859556B1 (en)
CN (1) CN1186095C (en)
AT (1) ATE234108T1 (en)
AU (1) AU764744B2 (en)
BR (1) BR9915800A (en)
CA (1) CA2353469A1 (en)
CZ (1) CZ295769B6 (en)
DE (2) DE19856897A1 (en)
DK (1) DK1137430T3 (en)
ES (1) ES2192880T3 (en)
HK (1) HK1040636B (en)
HU (1) HUP0104702A3 (en)
IL (2) IL143528A0 (en)
NO (1) NO328762B1 (en)
PL (1) PL202908B1 (en)
PT (1) PT1137430E (en)
RU (1) RU2243783C2 (en)
WO (1) WO2000033863A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (en) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
DE10035156A1 (en) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh New protein complex containing complex protein from botulinum toxin, useful for oral delivery of therapeutic polypeptide or low molecular weight pharmaceutical
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
US7763663B2 (en) * 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
US7183066B2 (en) * 2002-09-27 2007-02-27 Allergan, Inc. Cell-based fluorescence resonance energy transfer (FRET) assays for clostridial toxins
CA2518650A1 (en) * 2004-09-10 2006-03-10 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
WO2006138127A2 (en) * 2005-06-14 2006-12-28 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US8926991B2 (en) 2005-06-14 2015-01-06 Botulinum Toxin Research Associates, Inc. Botulinum toxin and the treatment of primary disorders of mood and affect
US20150258183A1 (en) 2006-06-07 2015-09-17 Botulinum Toxin Research Associates, Inc. Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect
CA2618655C (en) 2005-07-18 2015-12-22 University Of Massachusetts Lowell Compositions and methods for making and using nanoemulsions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
DK3144013T3 (en) 2005-12-01 2019-03-04 Univ Massachusetts Lowell Botulinum nanoemulsions
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (en) 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
BRPI0719756A2 (en) * 2006-12-01 2014-01-21 Anterios Inc Amphiphilic Nanoparticles
BRPI0719732A2 (en) 2006-12-01 2017-05-16 Anterios Inc peptide nanoparticles and uses thereof
KR20100050443A (en) 2007-05-31 2010-05-13 안테리오스, 인코퍼레이티드 Nucleic acid nanoparticles and uses therefor
CN105147608B (en) * 2008-06-26 2019-12-10 安特里奥公司 Dermal delivery
WO2010096134A1 (en) 2008-12-04 2010-08-26 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
JP2013510193A (en) * 2009-11-09 2013-03-21 サンダース，イラ Treatment of sleep-disordered breathing using neurotoxins
EP2677029B1 (en) 2011-05-19 2017-05-10 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
JP6156954B2 (en) 2012-11-21 2017-07-05 イプセン バイオイノベーション リミテッド Method for producing proteolytically processed polypeptide
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11311496B2 (en) 2016-11-21 2022-04-26 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551473A (en) * 1984-04-26 1985-11-05 Schossow George W Method of inhibiting snoring and obstructive sleep apnea
CA2138020C (en) * 1992-06-23 1999-02-16 Eric A. Johnson Pharmaceutical composition containing botulinum b complex
AU683275B2 (en) * 1993-06-10 1997-11-06 Allergan, Inc. Multiple botulinum toxins for treating neuromuscular disorders and conditions
EP1598077B1 (en) * 1993-12-28 2009-11-04 Allergan, Inc. Use of the neurotoxic component of botulinum toxins for the treatment of a spastic muscle
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation
US5756468A (en) * 1994-10-13 1998-05-26 Wisconsin Alumni Research Foundation Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
SE9504537D0 (en) * 1995-12-19 1995-12-19 Jan Hedner Ways of treating and diagnosing respiratory disorders during sleep and means of performing the method
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US9354569B2 (en) 2013-06-13 2016-05-31 Lexmark International, Inc. Heat transfer system for a fuser assembly

Similar Documents

Publication Publication Date Title
RU2001116080A (en) THERAPEUTIC AGENT FOR SUPPRESSING NOISE OF TAP
CZ20012058A3 (en) Therapeutic composition for suppressing snore
CA2047681A1 (en) Vaccines for nontypable haemophilus influenzae
ES2263408T1 (en) PREVENTION AND TREATMENT OF AMYLOIDOGENIC DISEASE.
NO964413L (en) Group A streptococcal polysaccharide, immunogenic mixtures thereof and use thereof
ES2271954T3 (en) LIPOPROTEIN EXPRESSION.
FI974385A0 (en) Preparation of xylitol For the purpose of pharmaceutical treatment and xylitol preparations For the manufacture of xylitol
MX9706095A (en) Multifunctional enzyme.
JPH04225924A (en) Subunit vaccine for pig actinobacillus
ATE211765T1 (en) NEW FAMILY OF PROTEASE INHIBITORS AND OTHER BIOLOGICALLY ACTIVE SUBSTANCES
DK1173476T3 (en) Functional soybean proteins
RU2004139053A (en) IMMUNOGENIC CONJUGATES
NO983054D0 (en) Viral recombinant pseudoparticles and use as vaccines and as anti-tumor agents
CA2368767A1 (en) Protease resistant flint analogs
RU2003100517A (en) NEW INTERFERON FOR THE TREATMENT OF MULTIPLE SCLEROSIS
Rose et al. Adult epiglottitis, cellulitis, and Streptococcus pneumoniae bacteremia
CA2527572A1 (en) Formulations containing thrombolytic agents for rectal administration
NO994806D0 (en) Peptide fragments of myelin basic protein, their pharmaceutical preparations and their use to treat multiple sclerosis
GB9910375D0 (en) Vaccine composition
PT95159B (en) A process for the preparation of a pharmaceutical composition comprising two plasminogen activators
KR950000158A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 20215 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000160A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 40057 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
KR950000157A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 10142 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections
EP0342015A3 (en) Peptides, their use and pharmaceutical compositions containing them
KR950000159A (en) Use of attenuated Pseudomonas aeruginosa CFCPA 30720 for the manufacture of a therapeutic and prophylactic vaccine for Pseudomonas aeruginosa infections